IL325202A - Antibodies against fibers (fibrils) - Google Patents

Antibodies against fibers (fibrils)

Info

Publication number
IL325202A
IL325202A IL325202A IL32520225A IL325202A IL 325202 A IL325202 A IL 325202A IL 325202 A IL325202 A IL 325202A IL 32520225 A IL32520225 A IL 32520225A IL 325202 A IL325202 A IL 325202A
Authority
IL
Israel
Prior art keywords
fibril antibodies
fibril
antibodies
Prior art date
Application number
IL325202A
Other languages
English (en)
Hebrew (he)
Original Assignee
Immutrin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2308884.2A external-priority patent/GB202308884D0/en
Priority claimed from GBGB2308898.2A external-priority patent/GB202308898D0/en
Application filed by Immutrin Ltd filed Critical Immutrin Ltd
Publication of IL325202A publication Critical patent/IL325202A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL325202A 2023-06-14 2025-12-07 Antibodies against fibers (fibrils) IL325202A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2308884.2A GB202308884D0 (en) 2023-06-14 2023-06-14 Anti-fibril antibodies
GBGB2308898.2A GB202308898D0 (en) 2023-06-14 2023-06-14 Anti-fibril antibodies
PCT/EP2024/066449 WO2024256583A1 (fr) 2023-06-14 2024-06-13 Anticorps anti-fibrilles

Publications (1)

Publication Number Publication Date
IL325202A true IL325202A (en) 2026-02-01

Family

ID=91580895

Family Applications (1)

Application Number Title Priority Date Filing Date
IL325202A IL325202A (en) 2023-06-14 2025-12-07 Antibodies against fibers (fibrils)

Country Status (7)

Country Link
KR (1) KR20260026033A (fr)
CN (1) CN121487964A (fr)
AU (1) AU2024304161A1 (fr)
CL (1) CL2025003893A1 (fr)
IL (1) IL325202A (fr)
MX (1) MX2025014924A (fr)
WO (1) WO2024256583A1 (fr)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1991000906A1 (fr) 1989-07-12 1991-01-24 Genetics Institute, Inc. Animaux chimeriques et transgeniques pouvant produire des anticorps humains
WO1992003917A1 (fr) 1990-08-29 1992-03-19 Genpharm International Recombinaison homologue dans des cellules de mammiferes
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
EP2305027B1 (fr) 1996-12-03 2014-07-02 Amgen Fremont Inc. Mammifères trangèniques obtenus par génie génétique contenant des loci des immunoglobulines humaines qui comprennent plusieurs régions de VH et de Vkappa, et anticorps aussi obtenus.
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6475220B1 (en) 1999-10-15 2002-11-05 Whiteside Biomechanics, Inc. Spinal cable system
WO2015092077A1 (fr) * 2013-12-20 2015-06-25 Neurimmune Holding Ag Thérapie de l'amyloïdose de la transthyrétine (ttr) à base d'anticorps, et anticorps d'origine humaine afférents
JP6818268B2 (ja) * 2014-01-29 2021-01-20 Ｋｍバイオロジクス株式会社 抗トランスサイレチンヒト化抗体
MX2020003041A (es) * 2017-10-06 2020-10-05 Prothena Biosciences Ltd Anticuerpos anti-transtiretina.
JP2023548005A (ja) * 2020-10-28 2023-11-15 ノヴォ ノルディスク アー／エス 抗トランスサイレチン抗体およびその使用方法

Also Published As

Publication number Publication date
CL2025003893A1 (es) 2026-01-30
CN121487964A (zh) 2026-02-06
KR20260026033A (ko) 2026-02-25
AU2024304161A1 (en) 2025-12-11
WO2024256583A1 (fr) 2024-12-19
MX2025014924A (es) 2026-02-03

Similar Documents

Publication Publication Date Title
GB202014851D0 (en) SARS-COV-2 antibodies
GB2614651B (en) Antibodies
GB2627309B (en) Antibodies
IL317231A (en) Antibodies against BCMA
GB202304512D0 (en) Antibodies
GB202217924D0 (en) Antibodies
GB202309981D0 (en) Antibody
GB202204159D0 (en) Antibodies
GB202008022D0 (en) Antibodies
IL325202A (en) Antibodies against fibers (fibrils)
IL320725A (en) Anti-beta-catenin antibodies
GB202400120D0 (en) Anti-pgdh antibodies
GB202319255D0 (en) Anti-UNC5C antibodies
GB202318820D0 (en) Antibodies
GB202317371D0 (en) Anti-unc5c antibodies
GB202317192D0 (en) Anti-agr2 antibodies
GB202317189D0 (en) Anti-AGR2 antibodies
GB202317188D0 (en) Anti-AGR2 antibodies
GB202317187D0 (en) Anti-AGR2 antibodies
GB202316016D0 (en) Antibodies
GB202311473D0 (en) Anti-ifnl1/reg3a antibodies
GB202311470D0 (en) Anti-BST2 antibodies
GB202309920D0 (en) Antibodies
GB202308898D0 (en) Anti-fibril antibodies
GB202308884D0 (en) Anti-fibril antibodies